EP Patent

EP3576740B1 — Cancer treatment

Assigned to Janssen Pharmaceutica NV · Expires 2023-06-14 · 3y expired

What this patent protects

Patent listed against Balversa.

Drugs covered by this patent

Balversa (ERDAFITINIB) · Johnson & Johnson

Patent Metadata

Patent number: EP3576740B1
Jurisdiction: EP
Classification: —
Expires: 2023-06-14
Drug substance claim: No
Drug product claim: No
Assignee: Janssen Pharmaceutica NV
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.